ARDT at a glance
Ardent Health, Inc. (ARDT, SEC CIK 1756655) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as September 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Ardent Health, Inc. (ARDT) reported revenue of $6.3 billion (up 6.0% from FY2024) and net income of $135.8 million. Diluted EPS was $0.96.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Ardent Health, Inc. (ARDT) shares worth $220.5 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by DeMichiei Robert on June 5, 2026 of 11,260 shares at $8.73 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.3B
- +6.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $220.5M · −1 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $1,624.9M, up $48.1M or 3.1% YoY, driven by adjusted admissions growth of 2.9%
- Net income attributable to Ardent $44.5M, margin 2.7% vs negative 1.5% YoY
- Medicaid supplemental payments $156.9M vs $186.5M YoY, the primary revenue headwind
- Cash $766.2M and available liquidity $1,009.8M at September 30, 2026
- Operating cash flow $258.4M vs $247.1M YoY, with $115.6M capital expenditures and $24.0M share repurchases year-to-date
Risk Factors
- No material changes to previously disclosed risk factors in the Annual Report
- Regulatory, legal, and compliance risks remain those identified in the Annual Report
- Operational and competitive risks remain those identified in the Annual Report
- Liquidity, debt, currency, and concentration risks remain those identified in the Annual Report
AI summary of the ARDT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Selling stockholders sold 8,000,000 shares at $14.50, increasing public float without diluting Ardent Health
- Ardent received no offering proceeds, limiting direct balance-sheet benefit from the transaction
Item 7.01: Regulation FD Disclosure
- Ardent Health agreement to acquire Boone Health, a Columbia, Missouri not-for-profit health system
- $47 million cash purchase price, creating a near-term cash deployment and acquisition funding consideration
Item EX-99.1: Item EX-99.1
- $47 million cash acquisition of Boone Health, including 392-bed hospital, 19 care sites and related real estate
- Boone Health adds approximately $480 million annual revenue and a 26-county Missouri service area
Item 2.02: Results of Operations and Financial Condition
- Ardent Health reported third-quarter fiscal 2026 results for the period ended September 30, 2026
- Press release issued November 4, 2026, with detailed financial results in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.625B, up 3.1% YoY, while adjusted admissions grew 2.9%, signaling improving utilization
- Net income attributable to Ardent $45M, or $0.31 diluted EPS, versus a $23M loss, or $(0.17), last year
AI summaries of ARDT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ARDT
Don't miss the next ARDT filing
- Alerts as it files. A push when ARDT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ARDT, by share count.
- Ask anything. An AI agent that reads every ARDT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| LUMSDAINE ALFRED | F | Sep 25, 2026 | 3,389 | $10.54 |
| Petrovich Stephen C. | F | Sep 25, 2026 | 788 | $10.54 |
| Byers David Raynor | F | Sep 25, 2026 | 524 | $10.54 |
| Caspers Dave | A | Jul 1, 2026 | 103,653 | - |
| DeMichiei Robert | Buy | Jun 5, 2026 | 11,260 | $8.73 |
| LUMSDAINE ALFRED | Buy | Jun 5, 2026 | 10,000 | $8.81 |
| Havdala Ellen | A | Apr 1, 2026 | 14,231 | - |
| LUMSDAINE ALFRED | A | Apr 1, 2026 | 53,846 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $5.4B | $6.0B | $6.3B | |
| Net Income | $53.9M | $210.3M | $135.8M | |
| Net Margin | 1.0% | 3.5% | 2.1% | |
| Balance Sheet | ||||
| Total Assets | $4.7B | $5.0B | $5.3B | |
| Equity | $670.9M | $1.1B | $1.3B | |
| ROE | 8.0% | 18.6% | 10.5% | |
| Per Share | ||||
| EPS | $0.43 | $1.58 | $0.96 | |
| Cash Flow | ||||
| Operating CF | $221.7M | $315.0M | $470.5M | |
Source: XBRL data in Ardent Health, Inc. (ARDT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ARDT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $220.5M |
| Q2 2026 | 28 | $191.2M |
| Q1 2026 | 25 | $154.3M |
| Q4 2025 | 23 | $161.9M |
| Q3 2025 | 23 | $248.8M |
| Q2 2025 | 24 | $120.5M |
| Q1 2025 | 19 | $90.8M |
| Q4 2024 | 14 | $231.8M |
- Morgan Stanley+354.4K (+112%)
- Dimensional Fund Advisors+334.0K (+231%)
- Vanguard Capital Management LLC+234.1K (+24%)
- Goldman Sachs Group+155.9K (+51%)
- Citadel Advisors LLC+143.7K (+127%)
- JPMorgan Chase & Co−113.8K (-47%)
- Mangrove Partners−38.0K (-46%)
- Bank of America Corp−16.2K (-4%)
- Wells Fargo & Co−15.1K (-77%)
- Citigroup−4.8K (-7%)
- Franklin Resources+322.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ARDT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 23, 2026 | - | Analysis | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 8-K | Sep 4, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 8-K | May 26, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
Related Health Care companies
- CYH · COMMUNITY HEALTH SYSTEMS INCServices-General Medical & Surgical Hospitals, NEC
- HCA · HCA HealthcareServices-General Medical & Surgical Hospitals, NEC
- SGRY · Surgery Partners, Inc.Services-General Medical & Surgical Hospitals, NEC
- UHS · Universal Health ServicesServices-General Medical & Surgical Hospitals, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
ARDT SEC filings: frequently asked questions
Which institutions hold ARDT stock?
As of September 30, 2026, the largest Ardent Health, Inc. (ARDT) holders among the 13F filers tracked by SignalX were Ventas ($96.6 million), BlackRock ($23.4 million), Ameriprise Financial ($22.4 million), AQR Capital Management ($15.6 million), Vanguard Capital Management LLC ($12.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ARDT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Ardent Health, Inc. (ARDT) reported revenue of $6.3 billion (up 6.0% from FY2024) and net income of $135.8 million. Diluted EPS was $0.96. The figures come from the XBRL data in the 10-K.
What did ARDT report in its latest 8-K?
Ardent Health, Inc. (ARDT) filed an 8-K on November 19, 2026 reporting Item 8.01 (Other Events). Selling stockholders sold 8,000,000 shares at $14.50, increasing public float without diluting Ardent Health.
What are the latest ARDT SEC filings?
Ardent Health, Inc. (ARDT) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on September 29, 2026.
What is ARDT's SEC CIK number?
Ardent Health, Inc. (ARDT)'s SEC Central Index Key (CIK) is 1756655. EDGAR lists every ARDT filing under that number.
Ask anything about ARDT
The research agent reads ARDT's filings, financials, insider trades and 13F holders, then answers with sources.